Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/2/2021 (updated 4/10/2024)
This webinar provided a review of basic principles of integrated behavioral health and an update on recent outcomes and implementation research.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 12/24/2020 (updated 4/4/2024)
The Townhall TeleECHO presentation will introduce a monthly interactive opportunity for clinicians and their support staff to address challenges and share solutions and successes to gain confidence in addressing OUD with MOUD. The Behavioral Health Data Learning Collaborative presentation will introduce goals of understanding data and data sharing, use of indicators and data sources, and data driven programming and quality improvement. Open discussion will follow each presentation.
Posted 8/25/2021 (updated 4/2/2024)
Created by the Association of State and Provincial Psychology Boards (ASPPB), the Psychology
Interjurisdictional Compact (PSYPACT) is an interstate compact that facilitates the practice of
psychology using telecommunications technologies (telepsychology) and/or
temporary in-person, face-to-face psychological practice.
Posted 9/1/2020 (updated 3/29/2024)
To raise awareness of increasing overdose events and deaths related to cocaine and other stimulant use, and to provide guidance to health care providers on clinically managing and preventing harm from cocaine and stimulant use disorders.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 4/20/2022 (updated 3/27/2024)
This updated (March 2020) TIP is intended to provide addiction counselors and other providers, supervisors, and administrators with the latest science in the screening, assessment, diagnosis, and management of co-occurring disorders (CODs).